临床分离产AmpC β-内酰胺酶阴沟肠杆菌的耐药性分析(英文)  

Characterization of AmpC β-lactamases produced by clinical isolates of Enterobacter cloacae

作　　者：凌保东[1] 余娴[1] 谢勇恩[1] 雷军[1] 

机构地区：[1]川北医学院,南充637007

出　　处：《中国抗生素杂志》2007年第2期104-107,I0001,共5页Chinese Journal of Antibiotics

基　　金：四川省重点科技项目(No.2006J013-030)资助。

摘　　要：目的研究我院临床分离阴沟肠杆菌的产AmpC酶耐药情况及ampC基因型。方法收集临床分离的耐药阴沟肠杆菌15株;检测产AmpC酶和超广谱β-内酰胺酶(ESBLs)的菌株;测定MIC值;PCR扩增检测ampC基因及序列测定。结果15株菌中8株菌(53.3%)产AmpC酶,3株菌(20.0%)产ESBLs。产AmpC酶的菌株除对亚胺培南全敏感外,对其它抗菌药不同程度耐药。ampC基因与阴沟肠杆菌ECLC074的ampC基因高度同源。结论产AmpC酶是阴沟肠杆菌对β-内酰胺类抗生素耐药的主要机制之一。阴沟肠杆菌ECLC074 ampC基因是我院主要的阴沟肠杆菌ampC基因型。产AmpC酶的阴沟肠杆菌常呈多重耐药,亚胺培南是治疗此类菌所致感染的最有效药物。Objective To determine the prevalence and genotype of chromosomal AmpC β-lactamases produced by clinical isolates of Enterobacter cloacae. Methods Fifteen randomly chosen piperacillin-resistant Enterobacter cloacae were isolated. AmpC β-lactamases and extended spectrum β-lactamases （ESBLs） were detected. MICs of antibacterials were determined, their ampC genes were amplified by PCR and PCR products were sequenced. Results Eight isolates （53.3%） produced AmpC β-1actamases and other 3 strains （20. 0%） produced ESBLs. AmpC β-lactamase producers were susceptible to imipenem, while they had different resistant rates to other antibacterials, The Enterobacter cloacae ECLC074 ampC gene and the ampC genes of these strains were highly homologous. The AmpC β-lactamases of 2 isolates had one amino acid residue mutation. Conclusions The production of AmpC β-lactamases in strains of Enterobacter cloacae is one of the main resistant mechanisms to β-1actam antibiotics. Enterobacter cloacae ECLC074 ampC gene is the main gene style of AmpC β-lactamases-producing Enterobacter cloacae. AmpC β-lactamase producers are multi-drug resistant and imipenem is the most effective antibiotic for treating infections caused by this kind of strains.

关 键 词：阴沟肠杆菌 头孢菌素酶 AMPC基因 

分 类 号：R378.2[医药卫生—病原生物学]